Histone Enzyme ASH1L Drives Cancer Spread to Bones Through Immune Cell Hijacking
New study reveals how cancer cells reprogram bone immune cells to fuel metastasis, offering potential therapeutic targets.
Summary
Researchers discovered that the histone methyltransferase ASH1L acts as a master switch enabling prostate cancer to spread to bones. The enzyme is amplified in over 40% of metastatic prostate cancers and works by reprogramming immune cells called macrophages in the bone environment. When cancer cells overexpress ASH1L, they hijack these immune cells, converting them into tumor-supporting allies that fuel metastatic growth. Blocking ASH1L significantly reduced bone metastases in mouse models and extended survival, suggesting this epigenetic pathway could be a promising therapeutic target for preventing cancer spread.
Detailed Summary
This groundbreaking study identifies ASH1L, a histone methyltransferase enzyme, as a critical driver of cancer metastasis to bones. Using comprehensive genomic analysis, researchers found that ASH1L is genetically amplified in over 40% of metastatic prostate cancers compared to localized tumors, and high ASH1L levels correlate with worse survival outcomes.
The research team used multiple experimental approaches including CRISPR gene editing, mouse models, and single-cell RNA sequencing to understand ASH1L's role. When they knocked out ASH1L in aggressive prostate cancer cells (PC-3M), bone metastases were completely prevented in mouse models (0% vs 67% in controls), and overall survival was significantly extended. Conversely, overexpressing ASH1L in less aggressive cells dramatically increased their metastatic potential.
The key mechanistic discovery involves ASH1L's partnership with HIF-1α to reprogram the bone microenvironment. Cancer cells with high ASH1L secrete factors like IGF-2 that convert bone-resident immune cells (monocytes) into lipid-associated tumor-associated macrophages (LA-TAMs). These reprogrammed immune cells then support tumor growth rather than fighting it, creating a pro-metastatic niche in the bone.
Using pharmacological inhibitors targeting the ASH1L-HIF-1α pathway, researchers achieved robust anti-metastatic responses in preclinical models. The study also revealed that ASH1L rewires cellular metabolism, specifically affecting oxidative phosphorylation in macrophages, which contributes to their tumor-supporting phenotype.
This research provides the first comprehensive evidence that epigenetic modifications in cancer cells can remotely reprogram immune cell metabolism and function in distant metastatic sites. The findings establish ASH1L as both a biomarker for metastatic risk and a potential therapeutic target, with immediate implications for developing combination therapies that target both cancer cells and their supportive microenvironment.
Key Findings
- ASH1L gene amplification occurs in >40% of metastatic prostate cancers vs localized tumors
- ASH1L knockout completely prevented bone metastases (0% vs 67% in controls, p<0.001)
- ASH1L depletion significantly extended overall survival in mouse models (log-rank p<0.05)
- High ASH1L expression correlates with worse survival in metastatic prostate cancer patients
- ASH1L overexpression increased bone tumor growth by >5-fold in mouse models
- Pharmacological ASH1L-HIF-1α pathway inhibition achieved robust anti-metastatic responses
- ASH1L drives conversion of monocytes to lipid-associated tumor-supporting macrophages via IGF-2
Methodology
The study used CRISPR/Cas9 gene editing in multiple prostate cancer cell lines (PC-3M, DU145, LNCaP), intracardiac and intratibial injection mouse models with bioluminescence tracking, single-cell RNA sequencing of bone microenvironment, comprehensive genomic analysis of human cancer databases (TCGA, SU2C), and pharmacological intervention studies. Sample sizes ranged from 6-12 mice per group with appropriate statistical tests including log-rank survival analysis and ANOVA.
Study Limitations
The study was primarily conducted in mouse models and prostate cancer cell lines, requiring validation in human clinical trials. The research focused mainly on prostate cancer, though ASH1L amplification occurs in other cancers. Long-term safety and efficacy of ASH1L-targeted therapies remain to be established. The authors noted funding from multiple cancer research organizations but did not report specific conflicts of interest related to therapeutic development.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.